成都康华生物制品股份有限公司 2024年度监事会工作报告 2024年度，成都康华生物制品股份有限公司（以下简称"公司"）监事会根 据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证 券法》（以下简称"《证券法》"）《成都康华生物制品股份有限公司章程》 （以下简称"《公司章程》"）及《成都康华生物制品股份有限公司监事会议事 规则》（以下简称"《监事会议事规则》"）等法律法规及公司内部制度的规 定，从切实维护公司利益和全体股东权益出发，认真履行了监督职能和义务， 检查了公司经营、财务活动及依法运作等情况，参与公司重大决策、决定的研 究，并列席了本年度召开的公司董事会及股东大会，对保障公司的规范运作和 稳健发展起到了积极作用。现将2024年监事会主要工作情况汇报如下： 一、报告期内监事会工作情况 根据《公司法》《证券法》《公司章程》及《监事会议事规则》的有关规定 和要求，公司监事会在2024年度召开了10次会议，认真审议相关事项，履行了监 事会的监督职责。同时，监事会密切关注公司经营运作情况，认真监督公司财务 及资金运作等情况，检查公司董事会和经营层职务行为，保证了公司经营管理行 为的规范。具体 ...

成都康华生物制品股份有限公司 2024 年年度财务报告 成都康华生物制品股份有限公司 2024 年年度财务报告 一、审计报告 | 审计意见类型 | 标准的无保留意见 | | --- | --- | | 审计报告签署日期 | 2025 年 04 月 17 日 | | 审计机构名称 | 立信会计师事务所（特殊普通合伙） | | 审计报告文号 | 信会师报字[2025]第 ZD10038 号 | | 注册会计师姓名 | 卫亚辉、袁竞艳 | 审计报告正文 成都康华生物制品股份有限公司全体股东： 一、 审计意见 我们审计了成都康华生物制品股份有限公司（以下简称康华生物）财务报表，包括 2024 年 12 月 31 日的合并及母公 司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相关财 务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了康华生物 2024 年 12 月 31 日 的合并及母公司财务状况以及 2024 年度的合并及母公司经营成果和现金流量。 二、 形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-015 成都康华生物制品股份有限公司 关于确认公司2024年度董事、监事和高级管理人员薪酬及 2025年度薪酬方案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚假 记载、误导性陈述或重大遗漏。 成都康华生物制品股份有限公司（以下简称"公司"）于2025年4月17日召 开第三届董事会第六次会议审议通过了《关于确认公司2024年度董事、高级管理 人员薪酬及2025年度薪酬方案的议案》，第三届监事会第六次会议审议了《关于 确认公司2024年度监事薪酬及2025年度薪酬方案的议案》，现将有关情况公告如 下： 一、确认2024年度董事、监事和高级管理人员薪酬 | 姓名 | 职务 | 2024 年税前薪酬 总额（万元） | | 备注 | | | --- | --- | --- | --- | --- | --- | | 王振滔 | 董事长 | | 237.45 | —— | | | 吴红波 | 董事、总裁 | | 173.70 | —— | | | 吴文年 | 董事、副总裁兼财务负责 人、董事会秘书 | | 117.91 | —— ...

成都康华生物制品股份有限公司 募集资金存放与使用情况专项报告 关于成都康华生物制品股份有限公司2024年度募集资金存 放与使用情况专项报告的鉴证报告 信会师报字[2025]第 ZD10040 号 二〇二四年度 成都康华生物制品股份有限公司全体股东： 贵公司董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求 （2022 年修订）》（证监会公告〔2022〕15 号）、《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以 及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告 格式》的相关规定编制募集资金专项报告。这种责任包括设计、执 行和维护与募集资金专项报告编制相关的内部控制，确保募集资金 专项报告真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第 3101 号——历 史财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。 该准则要求我们遵守职业道德规范，计划 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-019 成都康华生物制品股份有限公司 关于续聘2025年度审计机构的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚假 记载、误导性陈述或重大遗漏。 成都康华生物制品股份有限公司（以下简称"公司"）于2025年4月17日召开 第三届董事会第六次会议和第三届监事会第六次会议，审议通过了《关于续聘公 司2025年度审计机构的议案》，同意公司续聘立信会计师事务所（特殊普通合伙） 为公司2025年度审计机构。本次续聘符合《国有企业、上市公司选聘会计师事务 所管理办法》的相关规定。本事项尚需提交公司2024年年度股东大会审议。现将 具体情况公告如下： 一、 拟续聘会计师事务所的基本信息 （一）机构信息 1、基本信息 名称：立信会计师事务所（特殊普通合伙） 统一社会信用代码：91310101568093764U 成立日期：2011年01月24日 类型：特殊普通合伙企业 注册地址：上海市黄浦区南京东路61号四楼 注册资本：15900万元人民币 2、投资者保护能力 截至2024年末，立信已提取职业风险基金1.66亿元，购买的职业保险累计赔 ...

成都康华生物制品股份有限公司 一、 2024 年度财务决算报告 2024 年度财务决算及 2025 年度财务预算报告 成都康华生物制品股份有限公司（以下简称"公司"）2024 年度财务报表已经 立信会计师事务所（特殊普通合伙）审计，出具了标准无保留意见的审计报告。 会计师认为：公司财务报表在所有重大方面按照企业会计准则的规定编制，公允 反映了公司 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并 及母公司的经营成果和现金流量。 2024 年度，实现营业收入 143,187.66 万元，同比降低 9.23%；实现归属于上 市公司股东的净利润 39,865.19 万元，同比降低 21.71%；实现归属于上市公司股 东的扣除非经常性损益的净利润 45,749.50 万元，同比降低 15.75%。现将 2024 年度财务决算（合并口径）的相关情况报告如下： (一)主要资产情况 1、报告期内，应收账款较期初降低 7.91%，主要是公司回款额大于销售额 所致； 2、报告期内，货币资金较期初降低 3.66%，主要是公司分配现金股利及回 购股份增加所致； 3、报告期内，固定资产较期初增长 12 ...

Revenue and Financial Performance - The company's operating revenue for 2024 was ¥1,431,876,598, a decrease of 9.23% compared to ¥1,577,395,401 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥398,651,923, down 21.71% from ¥509,215,965 in 2023[25]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥457,495,046, a decrease of 15.75% from ¥543,046,767 in 2023[25]. - The total assets at the end of 2024 were ¥4,027,582,274, a decline of 4.32% from ¥4,209,268,312 in 2023[25]. - The basic earnings per share for 2024 was ¥3.0279, down 20.47% from ¥3.8073 in 2023[25]. - The weighted average return on equity for 2024 was 11.64%, down from 15.29% in 2023, a decrease of 3.65%[25]. - The net cash flow from operating activities for 2024 was ¥572,241,897, a slight decrease of 0.30% from ¥573,983,334 in 2023[25]. - The company reported a negative net profit of ¥7,250,303 in the fourth quarter of 2024, primarily due to losses from fair value changes of associated companies[27]. - The company received government subsidies amounting to ¥2,699,577 in 2024, compared to ¥851,890 in 2023[31]. - The company reported a total non-recurring loss of ¥58,843,123 in 2024, compared to a loss of ¥33,830,802 in 2023[32]. Product Development and Innovation - The company emphasizes ongoing product innovation and process improvement to enhance product safety and maintain competitive advantages in the market[8]. - The company is focused on strengthening its R&D team and mechanisms to mitigate development risks across multiple research directions[6]. - The company has established multiple vaccine research and development platforms and has participated in national and provincial scientific projects, enhancing its innovation capabilities[50]. - The company has developed a freeze-dried rabies vaccine using human diploid cells, which has improved virus yield and reduced production costs, while ensuring safety and immunogenicity[52]. - The company is developing a six-valent norovirus vaccine, with clinical trials approved in Australia and the US, expected to enhance market competitiveness[71]. - The company is developing a vaccine for the prevention of meningitis caused by ACYW135 group bacteria, with clinical trials planned after completing preclinical research[72]. - The company has seven major R&D projects underway, with the six-valent norovirus vaccine expected to enter clinical trials in 2024[43]. Market and Industry Trends - The global vaccine market size in 2023 is approximately 7 billion doses, valued at $77 billion, accounting for about 5% of the total global pharmaceutical market revenue[35]. - Major vaccine products such as HPV, pneumococcal, influenza, and shingles vaccines account for 70% of global vaccine sales, with expectations for continued growth in vaccination accessibility and public awareness post-pandemic[35]. - The global human vaccine market is projected to reach approximately $83.1 billion by 2025 and $131 billion by 2030, driven by increased health awareness and demand for infectious disease prevention[35]. - China's vaccine industry is transitioning from "scale expansion" to "innovation-driven" strategies, with a focus on mRNA, recombinant protein, and viral vector technologies[36]. - The number of domestically produced vaccines pre-certified by WHO is expected to increase to 18 by 2024, indicating significant improvement in international quality recognition[37]. - In 2023, 68 countries reported at least one vaccine shortage, highlighting a substantial global supply-demand gap in the vaccine market[37]. Corporate Governance and Compliance - The company has a governance structure that complies with relevant laws and regulations, ensuring equal rights for all shareholders[105]. - The board consists of 7 members, including 3 independent directors, ensuring a diverse skill set[106]. - The company held 10 board meetings during the reporting period, all conducted in accordance with legal requirements[106]. - The company has an independent internal audit department reporting to the audit committee, enhancing financial oversight[107]. - The company maintains transparency in information disclosure, ensuring timely and accurate communication with investors[109]. - The company operates independently from its controlling shareholders in terms of assets, personnel, and financial management[110]. Environmental Responsibility - The company obtained a revised pollutant discharge permit on March 20, 2023, with a validity of five years[158]. - The company has implemented a wastewater treatment process that includes multiple stages, ensuring compliance with discharge standards[160]. - The company has established an emergency response plan for environmental incidents, which was completed and filed with the local environmental bureau on January 28, 2023[160]. - The company adheres to various environmental protection laws and standards, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[158]. - The company has no instances of exceeding pollutant discharge limits during the reporting period[159]. - The company utilizes advanced technologies for waste gas treatment, including ultraviolet light purification and activated carbon adsorption[160]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of 10 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[8]. - The company plans to distribute a cash dividend of 20 RMB per 10 shares, totaling 129,946,899 RMB for the 2023 fiscal year[145]. - The total cash dividend, including other methods, amounts to 329,944,525.19 RMB, representing 100% of the total profit distribution[145]. - The company has established a competitive and fair compensation system to align employee income with business performance[139]. Risk Management - The company acknowledges risks associated with product development and sales, particularly in the context of long R&D cycles and external environmental changes[6]. - The R&D risk in the vaccine sector is high, with the need for extensive laboratory research, preclinical studies, and clinical trials before obtaining registration[38]. - The cycle from vaccine development to usage is long, divided into five stages: R&D, registration, production, distribution, and usage[38]. Marketing and Sales Strategy - The company is enhancing its brand and channel construction through various marketing strategies, including public education and participation in industry events[46]. - The company is focused on integrating internal and external marketing resources to optimize its sales management system and improve market coverage[47]. - The marketing strategy will be strengthened by training specialized sales personnel and optimizing the marketing management system to enhance brand influence and market coverage[98]. Employee Development and Corporate Culture - The company has established a robust talent development system to enhance employee skills and retain core talent, supporting long-term growth[56]. - The company emphasizes a culture of integrity, efficiency, innovation, and responsibility in its training and development initiatives[141]. - The training program includes both internal and external training, focusing on compliance and professional skills enhancement[141][142].

Financial Performance - The company's revenue for Q1 2025 was ¥137,942,758.51, a decrease of 55.70% compared to ¥311,367,042.84 in the same period last year[7]. - Net profit attributable to shareholders was ¥20,708,594.70, down 86.15% from ¥149,466,993.99 year-on-year[7]. - Basic and diluted earnings per share were both ¥0.1594, representing an 85.77% decrease from ¥1.1204 in the same period last year[7]. - Total operating revenue for the current period is ¥137,942,758.51, a decrease of 55.7% compared to ¥311,367,042.84 in the previous period[27]. - Net profit for the current period is ¥20,708,594.70, compared to ¥149,466,993.99 in the previous period, reflecting a significant decline[28]. - Total comprehensive income attributable to the parent company was CNY 20,708,594.70, compared to CNY 149,466,993.99 in the previous period, indicating a significant decrease[29]. Cash Flow and Assets - The net cash flow from operating activities was -¥16,686,433.97, a decline of 116.93% compared to ¥98,589,924.72 in the previous year[14]. - Current assets total ¥2,354,274,529.10, down from ¥2,488,001,102.09 at the beginning of the period, indicating a decrease of 5.4%[24]. - Cash and cash equivalents decreased to ¥931,949,521.90 from ¥1,001,326,623.71, a decline of 6.9%[23]. - The ending balance of cash and cash equivalents was CNY 681,949,521.90, down from CNY 1,007,828,965.84 in the previous period[32]. - The company reported a financial expense of -¥459,538.23, an improvement compared to -¥2,204,660.06 in the previous period[28]. Liabilities and Shareholder Information - Total liabilities amount to ¥415,450,340.07, a reduction from ¥580,073,577.69 in the previous period, representing a decrease of 28.5%[25]. - Total number of common shareholders at the end of the reporting period is 21,584[17]. - The largest shareholder, Aokang Group Co., Ltd., holds 12.26% of shares, totaling 16,305,468 shares, with 10,730,000 shares pledged[17]. - Wang Zhentao, a significant shareholder, owns 10.53% of shares, amounting to 14,004,687 shares, with 13,487,500 shares pledged[17]. - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for 29.87% of total shares[17]. Operating Costs and Revenue Decline - The company reported a 32.75% decline in revenue after excluding the previous year's one-time overseas authorization income of ¥106,240,500.00[7]. - The company's operating costs decreased by 36.97% to ¥7,686,111.19 due to reduced vaccine sales[12]. - Total operating costs for the current period are ¥112,232,733.05, down 16.8% from ¥134,855,630.79 in the previous period[27]. Changes in Assets - Total assets at the end of the reporting period were ¥3,883,667,631.05, down 3.57% from ¥4,027,582,273.97 at the end of the previous year[7]. - Non-current assets total ¥1,529,393,101.95, slightly down from ¥1,539,581,171.88 at the beginning of the period[24]. - Accounts receivable decreased to ¥1,211,775,915.46 from ¥1,298,879,167.25, a reduction of 6.7%[23]. - Inventory increased to ¥188,083,939.24 from ¥176,882,114.20, an increase of 6.7%[23]. Share Repurchase and Restricted Shares - The company has a total of 3,000,000 shares repurchased, representing 2.26% of total share capital, not included in the top 10 shareholders[18]. - The total number of restricted shares at the beginning of the period was 12,454,048, with 1,401,515 shares released during the period[21]. - The company has a total of 11,052,533 restricted shares remaining at the end of the reporting period[21]. - Wang Zhentao's restricted shares remain unchanged at 10,503,515 due to lock-up agreements[20]. Investment Activities - Cash inflow from investment activities was CNY 260,116,367.66, compared to CNY 50,000,000.00 in the previous period, showing a substantial increase[32]. - Cash outflow from investment activities totaled CNY 331,760,357.62, up from CNY 135,789,842.57 in the previous period[32]. Other Observations - The company experienced a 79.68% decline in fair value gains to ¥106,031.53, attributed to changes in the fair value of its equity investments[12]. - Other current assets increased by 4427.75% to ¥9,089,810.09, primarily due to withholding of corporate income tax from overseas authorization[15]. - The company reported a 68.23% decrease in payable employee compensation to ¥10,600,668.63, reflecting the distribution of 2024 annual salaries[15]. - The company did not report any net profit from merged entities during the current or previous periods[29]. - There are no new strategies or significant market expansions mentioned in the provided documents[22].

成都康华生物制品股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 证券代码：300841 证券简称: 康华生物 公告编号：2025-026 成都康华生物制品股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召 开了第三届董事会第六次会议，审议通过了《关于召开公司 2024 年年度股东大 会的议案》，决定于 2025 年 5 月 9 日召开 2024 年年度股东大会（以下简称"会 议"或"股东大会"），现将会议的有关事项通知如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召集、召开符合有关法律、 行政法规、部门规章、其他规范性文件及《公司章程》的有关规定。 4、会议召开的日期与时间 （1）现场会议召开时间：2025 年 5 月 9 日（星期五）下午 14:30 （2）网络投票时间：2025 年 5 月 9 日。其中，通过深圳证券交易所交易系 统进行网络投票的具体时间为：2025 年 ...

成都康华生物制品股份有限公司 第三届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届监事会第六次会 议通知已于2025年4月7日以专人送达、邮件等方式向全体监事发出。会议于2025 年4月17日在四川省成都市龙泉驿区北京路182号公司会议室以现场会议的方式 召开。会议由监事会主席吴淑青女士召集并主持，会议应出席监事3名，实际出 席监事3名。本次会议的召集、召开程序符合《中华人民共和国公司法》等法律、 法规、规范性文件和《成都康华生物制品股份有限公司章程》（以下简称"《公 司章程》"）、《成都康华生物制品股份有限公司监事会议事规则》的有关规定， 会议合法、有效。 二、监事会会议审议情况 证券代码：300841 证券简称：康华生物 公告编号：2025-009 公司编制和审核2024年年度报告及其摘要的程序符合法律、行政法规、中国 证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整，不存在虚假 记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯 ...